Progen Pharmaceuticals Limited (PGL)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Progen Pharmaceuticals Limited
Stock Code: PGL
GICS Sub-Industry: Biotechnology
Market Cap ($M): 11
Equiv. Shares (M): 55

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.190 $ 0.200 $ 0.200 $ 0.190 $ 0.200 20,000 $ -0.010  -5.000 %

Company Overview

Business Description:
Progen Pharmaceuticals Limited (PGL) is a biotechnology company focused on the discovery, development and commercialisation of small molecule pharmaceuticals therapeutics for cancer and other serious diseases. PGL develops of the anti-angiogenesis and anti-metastatic oncology products. PGL focuses on two main anti-cancer product developments, which are PG545 and Muparfostat (PI-88). PGL has operations in Australia and USA.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -1.8 -3.3 -- 0.0 0.0 0.0 --
2013  A -2.1 -7.5 -- 0.0 0.0 0.0 --
2012  A -3.4 -12.6 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $198 M -- 6.3117 0.3108 61.6883 8.4369 6.4363 0.00 0.00 0.00
CSL (CSL) $39,437 M 0.0899 0.2412 0.0806 29.0615 23.4149 21.6683 1.44 1.73 1.93
Mesoblast (MSB) $1,358 M -- -- -- -- -- -- 0.00 0.00 0.00
Progen Pharmaceuticals (PGL) $11 M -- -- -- -- -- -- 0.00 -- --
Sirtex Medical (SRX) $1,526 M 0.2906 0.5153 0.3535 65.3753 43.1448 31.8772 0.52 0.64 1.03

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
PGL -- -- 1.31 -- 1.90
Market 1.14 13.7 0.99 1.02 3.00
Sector 0.81 17.3 2.55 1.23 7.26

Name Position Start Date
Mr Indrajit (Jitto) Solomon Arulampalam Chief Executive Officer,Executive Chairman 12 July 2013
Mr Heng H Tang Executive Director,Managing Director 17 July 2009
Dr Hongjen Chang Non-Executive Director 29 November 2013

Name Position
Leslie Tillack Chief Executive Officer - PharmaSynth
Blair Lucas Company Secretary
Fleur Lankesheer Director - Business Development and Legal
Lee Horobin General Manager - Finance

Substantial Shareholders
Holding Name
6,700,000 (12.12%) TBG Inc
4,192,964 (7.58%) Medigen Biotechnology Corp.
5,000,000 (9.04%) Well Hallmark Holding Corp

Calendar of Events
Date Event
12 November 2015 Report (Annual)
28 September 2015 Report (Annual)
25 August 2015 Report (Prelim)
26 February 2015 Report (Interim)
12 December 2014 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Shares via SMSFs

An educational booklet that outlines how to get the most from your share investments for retirement thorugh your self managed super fund.

More details...


Australian Share Market - Close Up

CMC Markets 11/11/2014 | The Australian share market is in a decision zone - and trading from here may set the direction for the rest of the year.

Prices slashed - everything must go!

Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 | “If you want to have a better performance than the crowd, you must do things differently from the crowd.” Sir John Templeton.

Aussie share market bulls now have company

Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 | Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.

The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?


Sponsored Links